Cargando…
Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596402/ https://www.ncbi.nlm.nih.gov/pubmed/34137492 http://dx.doi.org/10.1111/dth.15030 |
| _version_ | 1784600360351956992 |
|---|---|
| author | Megna, Matteo Potestio, Luca Fabbrocini, Gabriella Cinelli, Eleonora |
| author_facet | Megna, Matteo Potestio, Luca Fabbrocini, Gabriella Cinelli, Eleonora |
| author_sort | Megna, Matteo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8596402 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85964022021-11-22 Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? Megna, Matteo Potestio, Luca Fabbrocini, Gabriella Cinelli, Eleonora Dermatol Ther Letters John Wiley & Sons, Inc. 2021-06-22 2021 /pmc/articles/PMC8596402/ /pubmed/34137492 http://dx.doi.org/10.1111/dth.15030 Text en © 2021 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letters Megna, Matteo Potestio, Luca Fabbrocini, Gabriella Cinelli, Eleonora Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title | Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title_full | Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title_fullStr | Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title_full_unstemmed | Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title_short | Tildrakizumab: A new therapeutic option for erythrodermic psoriasis? |
| title_sort | tildrakizumab: a new therapeutic option for erythrodermic psoriasis? |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596402/ https://www.ncbi.nlm.nih.gov/pubmed/34137492 http://dx.doi.org/10.1111/dth.15030 |
| work_keys_str_mv | AT megnamatteo tildrakizumabanewtherapeuticoptionforerythrodermicpsoriasis AT potestioluca tildrakizumabanewtherapeuticoptionforerythrodermicpsoriasis AT fabbrocinigabriella tildrakizumabanewtherapeuticoptionforerythrodermicpsoriasis AT cinellieleonora tildrakizumabanewtherapeuticoptionforerythrodermicpsoriasis |